IGES Pharma at the BIO International Convention

𝐓𝐡𝐞 𝐁𝐈𝐎 𝐈𝐧𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧 𝐡𝐚𝐬 𝐜𝐨𝐦𝐞 𝐭𝐨 𝐚𝐧 𝐞𝐧𝐝—𝐰𝐞’𝐯𝐞 𝐠𝐚𝐢𝐧𝐞𝐝 𝐦𝐚𝐧𝐲 𝐧𝐞𝐰 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐡𝐚𝐝 𝐥𝐨𝐭𝐬 𝐨𝐟 𝐢𝐧𝐬𝐩𝐢𝐫𝐢𝐧𝐠 𝐜𝐨𝐧𝐯𝐞𝐫𝐬𝐚𝐭𝐢𝐨𝐧𝐬

As the doors close on the final day, the IGES Pharma team is looking back on days filled with inspiring conversations, cutting-edge life science innovations, and strong partnerships. Navigating the complexities of European market access and launch optimization is always easier when you are surrounded by the best minds in the industry.

It was fantastic to have our team on the ground connecting with partners, clients, and old friends. A huge shoutout to Chus Castillo Gutierrez and Tilo Mandry for representing IGES Pharma so brilliantly throughout the event, bringing our specialized market access and health economics expertise to the global stage.

We were also thrilled to collaborate closely on-site with Thomas Frei from athagoras Group. As part of the athagoras Group, we love showcasing how combining tech-driven solutions with deep regulatory and pricing expertise accelerates next-generation therapies for patients worldwide.

Thank you to everyone who sat down with us to discuss the future of pharma. The energy this year was unmatched, and we’re leaving energized for the next steps!

See you at Bio Europe in Cologne in November 2026 or next year at Bio 2027 in Philadelphia.

IGES Pharma at the BIO International Convention
IGES Pharma at the ISPOR Convention
IGES Pharma at the World EPA Congress
IGES Pharma is taking part in the World EPA 2026 the world leading healthcare evidence, pricing and access congress.
Reimbursement and Pricing of Pharmaceuticals in Europe
IGES Pharma’s brochure “Reimbursement and Pricing of Pharmaceuticals in Europe” has become a highly sought-after source of information and has therefore been newly published for the eighth time. The focus of the new edition is on the harmonized HTA procedure applicable throughout the EU, known as Joint Clinical Assessment (JCA), which came into force in January 2025 and will be gradually introduced until 2030. It already applies to cancer drugs with innovative active ingredients (including orphan cancer drugs) and Advanced Therapy Medicinal Products (ATMPs), and will then apply to all orphan drugs with innovative active ingredients from January 2028 and finally to all drugs with innovative active ingredients from January 2030.
IGES Pharma at ESMO Congress 2025
The ESMO Congress is one of the most important international conferences in the field of oncology. It serves as a platform for the exchange of the latest research results, groundbreaking treatment methods, and innovative technologies in the field of cancer medicine. The ESMO Congress is held annually and will take place for the first time in Berlin from October 17 to 21, 2025, at the Messe Berlin exhibition center.
New branch in Spain: IGES Pharma now with locations in eight European countries
Further growth of the IGES Group – Consulting services for the pharmaceutical markets in Europe: EU4+UK and beyond
Independent marketing instead of out-licensing? Panel discussion at Bio Europe Spring
In recent years, the number of pharmaceutical companies that only commercialize a single drug has risen sharply. This is because more and more biotech companies are deciding not to out-license the drug they have developed, but to bring it onto the market themselves. What are the reasons for this increase? Why are biotech start-ups deciding against out-licensing? Is independent commercialization economically successful in the long term? These questions will be the focus of a panel discussion organized by the IGES Group at the BIO-Europe Spring convention on 18 March 2025 at 10.00am. Bio Europe Spring is one of the largest life sciences conventions of its kind in Europe.
Reimbursement and Pricing of Pharmaceuticals in Europe
Due to high demand, IGES experts have reissued the successful guide on the European reimbursement and pricing systems for pharmaceutical products. It also provides updated information on the harmonisation of the benefit assessment of new therapies at EU level. The new EU HTA process has been effective since January 2025 and is one of the most important projects in the field of European pharmaceutical regulation.
IGES founds new subsidiary in Italy: IGES Italy Pharma Consulting
Further growth of the IGES Group - Consulting services for the pharmaceutical markets in Europe
Panel at BIO-EUROPE: Start early, seek advice, talk to the HTA Agencies
EU-HTA will start in time in 69 days. Fundamental implementing acts adopted – preparations under time pressure but will finish in time.
IGES Pharma at BIO Japan 2024
IGES Pharma is taking part in the BIO Japan 2024 convention, the second largest industry event of its kind for the biopharmaceutical sector. The focus is on dialogue with innovative Asian biopharmaceutical companies on market access and reimbursement in Europe.
Santoke Naal from IGES at the BIO 2024 International Convention: "It is important to engage much earlier with the HTA-Agencies than before.”
The panel “Europe's Policy Environment and the Impact on the Biotech Sector” analyzed the proposed revisions to the General Pharmaceutical Legislation (GPL) , including changes to regulatory data protection.
Expert discussion with IGES: Focus on transatlantic cooperation in the biotech sector
The world's largest biotech congress of its kind, the BIO International Convention, has a strong European focus this year. With the participation of the IGES Group, it brings together major European pharmaceutical and biotech stakeholders to discuss the latest changes in EU legislation and their consequences for the transatlantic pharmaceutical market. The congress will be held in San Diego, California, from 3 to 6 June. More than 20,000 visitors are expected to attend.
IGES Group with HTA experts at BIO-Europe Spring 2024
The IGES Group is once again taking part in BIO-Europe Spring, one of the largest trade fairs of its kind for the life sciences sector in Europe. The main focus will be on the exchange of information on the European Health Technology Assessment (HTA) procedure, EU-HTA.
Current documents on the EU-HTA process and opportunity to provide feedback
On March 5, 2024 the draft implementing regulation was published for public consultation on the “have your say” homepage of the EU – and is open for feedback for four weeks until 02 April 2024.
12 January 2025 - The Countdown runs
Pharmaceuticals and medical devices - the countdown runs! January 12, 2025, the era of national product assessments ends and the application of the EU HTA Regulation begins.
IGES Life Science at the health economics conference ISPOR Europe 2023
The IGES Group will once again be present at the European conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The focus will be on the new, centralized HTA procedure, EU-HTA. As part of the scientific program, IGES experts will present current analyses on orphan drugs. ISPOR Europe 2023 will take place from November 12 to 15 in Copenhagen.
EU HTA harmonisation under time pressure: discussion at the biotech congress "BIO Europe 2023"
The time pressure due to EU HTA harmonisation is growing. In less than 15 months, the first medicinal products must undergo a central, EU-wide clinical evaluation procedure. The procedure itself is also taking place under high time pressure - with very tight deadlines and largely parallel to the marketing authorisation. What companies should urgently do now to successfully bring their new developments through the procedure is the topic of an IGES expert event at BIO Europe 2023 on 07 November in Munich.
IGES sets up a new subsidiary in France – IGES France Pharma Consulting
Continuation of its European growth course – Expansion of the services for pharmaceutical companies in Europe
IGES acquires majority stake in Synergus RWE – a European Medtech market access specialist
Continuation of its European growth course – Expansion of services for manufacturers of medical devices - Integration of the use of Scandinavian medical registries

Bringing Innovations to European Patients

IGES Pharma at the BIO International Convention